Technology ID
TAB-4606

Synthesis and Characterization of d8-JD5037 for Drug Discovery Studies

E-Numbers
E-012-2019-0
Lead Inventor
Iyer, Malliga (National Institute on Alcohol Abuse and Alcoholism (NIAAA))
Co-Inventors
Cinar, Resat (National Institute on Alcohol Abuse and Alcoholism (NIAAA))
Coffey, Nathan (National Institute on Alcohol Abuse and Alcoholism (NIAAA))
Applications
Therapeutics
Research Materials
Development Stages
Pre-Clinical (in vitro)
Research Products
Human Cell Lines
Computational models/software
Lead IC
NIAAA

This technology includes synthesis of S-2-((S)-3-(4-chlorophenyl)-N'-((4-chlorophenyl) sulfonyl)-4-phenyl-4,5-dihydro-1 H-pyrazole-1-carboximidamido)- 3-(methyld3) butanamide-d5, octadeuterated JD5037 for possible use in clinical Absorption, Distribution, Metabolism, and Excretion (ADME) studies for drug discovery studies.

Commercial Applications
Use in ADME studies for drug discovery.

Competitive Advantages
Novel; first synthesis of d8-JD5037.

Request More Info

Licensing Contact:
Shmilovich, Michael
shmilovm@nih.gov

Publications

  • Iyer M, Cinar R, et al. https://pubmed.ncbi.nlm.nih.gov/28545167/ [PMID 28545167]

Collaborations

  • Licensing

Collaboration Description

  • We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology.
Date Published